Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQF3250 in Type 2 Diabetes Mellitus Complicated With Overweight or Obesity
NCT07747857Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing TQF3250 capsules with TQF3250 Placebo (2 arms). Primary endpoints: Adverse Event and Abnormal clinical examination findings. Started Aug 2026; status: recruiting.
02
Drugs
TQF3250
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07747857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747857.